Chemed Reports Q3 Results, Expects 2026 Adjusted EPS at or Above Guidance High End
VITAS revenue rose 12.2% year over year to $457.4 million, while Roto-Rooter revenue increased 7.5% to $233.5 million. Chemed expects full-year 2026 adjusted EPS at or slightly above the high end of prior guidance.
Chemed reported Q3 2026 results: VITAS revenue $457.4M, up 12.2% YoY; Roto-Rooter revenue $233.5M, up 7.5% YoY. It expects full-year 2026 adjusted EPS at or slightly above the high end of prior guidance.Material DetailsContext by AI AnalystThis is a mid-cycle confirmation of improving trends at VIT…